Table 1.
Participant characteristics and cognitive data.
| Age (yrs) | |
| Mean (±SD) | 66.6 ± 10.2 |
| Range (min-max) | 25–95 |
| Sex | |
| Male:female | 1169:779 |
| Disease duration (yrs) | |
| Mean (±SD) | 9.25 ± 6.1 |
| Range (min-max) | 1–45 |
| Tremor predominant, % sample | 72% |
| Living situation (% sample) | |
| Living at home | 98.1% |
| Skilled care | 1.9% |
| Hoehn-Yahr staging | |
| Mean (±SD) | 2.49 ± 0.8 |
| Staging (% sample) | |
| Stage 1 | 13.9 |
| Stage 2 | 59.0 |
| Stage 3 | 21.1 |
| Stage 4 | 3.6 |
| Stage 5 | .4 |
| Medications (% sample taking) | |
| − Levodopa | 82 |
| − Dopamine agonists | 41 |
| − Antidepressants | 46 |
| − Cognitive enhancers | 29 |
| − Stimulant | 2 |
| Cognitive measures (mean ± SD) | |
| − Semantic fluency (animals) | 19.1 ± 6.2 |
| − 90″ Delayed recall (max = 5) | 3.0 ± 1.3 |
| Body mass index, mean ± SD | 27.3 ± 5.4 |
Variables are reported as means ± standard deviations (SD’s) with additional range data for certain variables.